866777-92-6Relevant articles and documents
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation
Long, Daniel D.,Armstrong, Scott R.,Beattie, David T.,Choi, Seok-Ki,Fatheree, Paul R.,Gendron, Roland A.L.,Genov, Daniel,Goldblum, Adam A.,Humphrey, Patrick P.,Jiang, Lan,Marquess, Daniel G.,Shaw, Jeng-Pyng,Smith, Jacqueline A.M.,Turner, S. Derek,Vickery, Ross G.
, p. 6048 - 6052 (2012)
Utilization of Theravance's multivalent approach to drug discovery towards 5-HT4 receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of a quinolone-tr
Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
-
Page/Page column 20, (2008/06/13)
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.